Nektar Therapeutics
NKTR
Delayed Nasdaq - 11/16 10:00:00 pm
38.23USD
+0.1%
Prev.38.1900
Open38.2000
High38.9900
Low37.4600
Volume3 593 436
Financials
Sales 2018 1 177 M
EBIT 2018 698 M
R. net 2018 681 M
Tréso. 2018 268 M
Rend. 2018 -
P/E ratio 2018 9,94
P/E ratio 2019
EV / Sales 2018 5,40x
EV / Sales 2019 26,0x
Capitalization 6 617 M
Company
Nektar Therapeutics is a clinical-stage biopharmaceutical company, which engages in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms.It operates through the United States and Europe geogrpahical segments.The company was founded in 1990 and is...
Sector :
Biotechnology & Medical Research - NEC
Calendar :
2018-12-03 Presentation
Trading Rating :
Investor Rating :
Latest news
11/15BIOCENTURY - MANAGEMENT TRACKS : Ascletis, Agenus
AQ
11/14NEKTAR THERAPEUTICS : Appoints Wei Lin, M.D., as Senior Vice President of Clinical Development and Head of 's Oncology Programs
PR
11/13Nektar makes case for NKTR-214 optimism
AQ
11/10ROBBINS ARROYO LLP : Nektar Therapeutics (NKTR) Misled Shareholders According to Class Action
BU
11/10NEKTAR THERAPEUTICS : Presents New Clinical and Preclinical Data for its Immuno-Oncology Pipeline at the 2018 Society for Immunotherapy of Cancer (SITC) Annual Meeting
PR
11/10KESSLER TOPAZ MELTZER & CHECK, LLP : Securities Fraud Class Action Filed Against Nektar Therapeutics - NKTR
PR
11/08KESSLER TOPAZ MELTZER & CHECK, LLP : – Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar Therapeutics
BU
11/08LEAD PLAINTIFF DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Nektar Therapeutics To Contact The Firm
PR
Technical analysis trends
Short TermMid-TermLong Term
TrendBearishBearishBearish
Resistance40,750,666,5
Spread/Res.-6,0%-24%-43%
Spread/Supp.12%12%12%
Support34,034,034,0